Business Wire

Veza, the Data Security Platform Built on the Power of Authorization, Announces Partnership with Google Cloud

Share

Veza, the data security platform built on the power of authorization, announces today that the company has entered a partnership with Google Cloud, including product integration that enables Google Cloud customers to harness the capabilities of Veza’s data security platform across their multi-cloud ecosystem.

Veza, which recently launched in April 2022 after two years of building in stealth, makes it easy to understand, manage, and control who can and should take what action on what data. With this new integration, Google Cloud customers can now directly access the capabilities of Veza’s authorization-based data security platform integrated with Google Cloud Policy Analyzer to identify, manage, and control external identities and service accounts to Google Cloud services (Looker, BigQuery, and more). This partnership furthers the relationship between Google and Veza, which began in 2021 when GV led the Series B investment in Veza and GV Partner Karim Faris joined Veza Board of Directors.

“The cloud is quickly becoming the primary footprint for organizations. By prioritizing and investing in security, Google Cloud has earned a differentiated position in the market,” said Tarun Thakur, Co-founder and CEO, Veza. “The initial product integration between Veza and Google Cloud, publicly demonstrated at the Google Cloud Security Summit in May this year, is a powerful example of how intelligence from Veza’s Authorization Graph can bolster the data security of Google Cloud customers. It shows how identity-to-data relationship insights from the Veza platform can be pulled directly into the Google Cloud Policy Analyzer, allowing customers to secure both Google Cloud data (Looker, BigQuery, Google Storage Buckets, etc.) to which multi-cloud identities (AD, Azure AD, Okta, etc.) have permissions and multi-cloud data (AWS, Snowflake, etc.) that is being accessed by Google Cloud identities.”

“Securing cloud environments and data from cybercrime and threats is a key priority of organizations across the globe,” said Sunil Potti, General Manager and Vice President, Cloud Security, Google Cloud. “With Veza’s platform now available alongside Google Cloud’s secure and global infrastructure, customers will be able to quickly deploy the solutions they need to better understand, control, and securely take action on their data across their multi-cloud environments.”

Veza’s data security platform aggregates identity information from humans, service accounts, and cloud IAM entities, and authorization data from apps and data systems, giving organizations a centralized, SaaS-based control plane to visualize, manage, and control data access controls through Veza’s Authorization Graph. Veza integrates with cloud identity providers, SaaS and custom apps, and data systems, and translates system-specific entitlements and permissions into a common, human-understandable business language, visualized in the platform as effective permissions. The platform brings a novel approach to data security by enabling organizations to address key data security use cases across access reviews and certifications for SaaS apps and data systems, privileged access management to data and apps, data lake security and governance, management of cloud entitlements, and much more. It delivers prioritized insights, provides access workflows, and actionable recommendations for remediation of over-privileged accounts, enabling security and IT teams to correct anomalies and right-size their organization’s permissions to protect against ransomware and other data breaches.

As organizations continue to adapt to the evolving demands of hybrid remote and in-office work, multi-cloud and hybrid-cloud environments — those with multiple providers of disparate data, app, compute, and infrastructure systems — are becoming the norm. According to the Flexera 2022 State of the Cloud Report, 89% of companies surveyed are multi-cloud, with only 2% operating in single private clouds and 9% in single public clouds. This trend is leading to a distributed web of data, relationships, and access points that are changing and difficult to track and secure.

Veza and Google Cloud already have a number of joint customers deployed across the industries of SaaS software, marketing technology, and media, including Vox Media.

“To support Vox Media’s growth and increasing M&A activity without compromising security, we need to ensure that across all of our brands, the right users have access only to the data they need access to, and that we have full visibility over what they can do with that data,” says Ateeb Ahmad , Senior Director, IT Infrastructure, Vox Media. With Veza and Google Cloud working together, we’ve been able to seamlessly manage access controls over our data for our largest merger to date, and tightly scope identity-to-data permissions even as our footprint with Google Cloud and other technologies grows.”

“The greatest gifts of the multi-cloud and the generational architectural shift of the modern data systems are also its greatest risks: securing data, scalability, flexibility, and seamless collaboration,” says Thakur. “When organizations enable workers to reach from one cloud to another to leverage data across their entire multi-cloud ecosystem, they foster growth, enable more intelligence, and promote agility. However, such apps and data systems are also more porous and are at increased risk of cybercrime and ransomware. We purpose-built Veza’s Core Authorization Platform for the multi-cloud so that organizations can implement strong access governance policies - Veza continuously evaluates these policies and enables both automated workflows for access reviews, automated access removal for toxic and stale combinations, and facilitates access grant and request for any app, data, and service.”

Learn More:

Google Cloud Security Summit - Best practices for defining and enforcing policies across your Google Cloud environment

Veza for Google Cloud demo
Veza for Google Cloud
Veza Free Trial - sign up here

About Veza

Veza is the data security platform built on the power of authorization. Our platform is purpose-built for hybrid multi-cloud environments to help you use and share your data safely. Veza makes it easy to understand, manage, and control who can and should take what action on what data. We organize authorization metadata across identity providers, data systems, cloud service providers, and SaaS applications — all to address the toughest data security challenges of the modern era. Founded in 2020, the company is funded by top-tier investors including Accel, Bain Capital, Ballistic Ventures, Blackstone, GV, Norwest Venture Partners, and True Ventures. To learn more, please visit us at veza.com. You can follow us on LinkedIn or on Twitter @vezainc.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Aircover PR
veza@aircoverpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye